Minnesota-based medtech giant St. Jude Medical (NYSE:STJ) is broaching new ground in the spinal pain market with the $200 million acquisition of NeuroTherm, maker of radiofrequency ablation therapies.

The acquisition bolsters St. Jude’s chronic pain portfolio with a device that comes into play earlier in the ‘chronic pain continuum,’ the company said. The deal would also make St. Jude the only company to offer both radiofrequency ablation and spinal cord stimulation devices.

The all-cash deal is slated to close before the end of the 3rd quarter, and St. Jude expects NeuroTherm to add about $10-$15 million to 2014 revenues. Excluding acquisition-related costs, the deal is expected to be neutral to St. Jude’s per-share earnings for the year, but will be accretive thereafter.

"NeuroTherm’s radiofrequency ablation products are an ideal complement to St. Jude Medical’s chronic pain portfolio, providing our global sales force with additional interventional pain therapies that offer potential relief to patients earlier in the chronic pain continuum," St. Jude COO Michael Rousseau said in prepared remarks. "As the only medical device manufacturer with both RFA and spinal cord stimulation, this acquisition will enable us to offer more treatment options to patients worldwide who suffer from the debilitating effects of chronic pain."

NeuroTherm develops minimally invasive radiofrequency ablation systems, intradiscal catheters and a suite of vertebral augmentation technologies. The company was built in part on a 2010 acquisition of Smith & Nephew’s (FTSE:SN, NYSE:SNN) spine pain management line, the terms of which were not disclosed.

Wall Street hasn’t moved much on the news today, with STJ shares down 0.5% to $69.69 as of about 11:55 a.m. EST. The stock has gained about 7% over the last month and is up 12.5% since the start of this year.